Molecular Biology Research Technique
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Tome Biosciences, a High-Profile Gene Editing Startup, Announces Massive Layoffs and Sale Plans
Tome Biosciences, gene editing, layoffs, startup, biotech, financial struggles
Tome Biosciences Halts Operations Amid Financial Strains, CEO Focuses on Strategic Deals
Tome Biosciences, gene editing, layoffs, financial struggles, strategic options, Rahul Kakkar
Gene Editing Biotech Tome Scales Back Operations Despite $213M Funding Round
Gene editing, biotech, Tome, funding, investor sentiment, layoffs, reorganization
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?
Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition
Pressure Points: Understanding Their Role in Self-Defense and Health
Pressure Points, Self-Defense, Knockout Techniques, Acupressure, Health Benefits, Pain Relief
Arc Institute Unveils Revolutionary Bridge Editing Technology for Programmable Genome Design
Bridge editing, genome design, programmable gene editor, DNA strands, Arc Institute, CRISPR, RNA-guided systems, genetic engineering
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology